Disclosures: Brandon Lehrich: Nothing to Disclose, Junyan Tao: Nothing to Disclose, Silvia Liu: Nothing to Disclose, Theo Hirsch: Nothing to Disclose, Tyler Yasaka: Nothing to Disclose, Catherine Cao: Nothing to Disclose, Evan Delgado: Nothing to Disclose, Yuqing Liu: Nothing to Disclose, Xiangnan Guan: Nothing to Disclose, Shan Lu: Nothing to Disclose, Long Pan: Nothing to Disclose, Sucha Singh: Nothing to Disclose, Minakshi Poddar: Nothing to Disclose, Aatur Singhi: Nothing to Disclose, Jessica Zucman-Rossi: Nothing to Disclose, Yulei Wang: Nothing to Disclose, Satdarshan (Paul) Monga: Alnylam: Grant/Research Support, Alnylam: Consultant, Surrozen: Independent Contractor, Fog Pharmaceuticals: Grant/Research Support, Mermaid Bio: Advisor, Vicero: Advisor, AntlerA: Advisor, Genentech: Speaking and Teaching, Surrozen: Consultant 2563 FULL LIVER CELL ATLAS OF FHF MOUSE MODEL REVEALS HSPCS AS REGULATORY HUB PROMOTING HEPATIC MICRO-ENVIRONMENT REBUILDING DURING MSC TREATMENT Jun Li 1 Heng Yao 1 Hui Yang 1 Suwan Sun 1 Xi Liang 2 Jing Jiang 1 Jiaojiao Xin 1 Dongyan Shi 1 Xin Chen 1 , 1 Zhejiang University, 2 Taizhou Central Hospital Background: Transplantation of human bone marrow mesenchymal stem cells (hBMSCs) can rescue mice with fulminant hepatic failure (FHF)
Safety Comparison Table# Research Evidence Comparison# Amycretin Research# Amycretin has early but impressive data: Phase 1 (SC): Published in The Lancet (2025)
Typically, 812 sessions, taken once a week, followed by maintenance doses, show noticeable improvement
Annu Rev Pathol 10 : 473510
